Clinical Trial Update: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on the safety and efficacy of Natalizumab in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED